Product Description
Loteprednol (Lotemax) is used to reduce eye swelling caused by allergies, certain eye infections, ocular rosacea (condition that can cause swelling, redness, and itching of the eye), herpes zoster (shingles; a rash that can occur in people who have had chickenpox in the past and can affect the eyes), and other eye conditions. Loteprednol is in a class of medications called corticosteroids. It works by stopping the release of certain natural substances that cause swelling, itching, and pain. (Sourced from: https://medlineplus.gov/druginfo/meds/a619025.html)
Mechanisms of Action: Corticosteroid Hormone Receptor Agonist
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Topical,Ophthalmic
FDA Designation: None *
Approval Status: Approved
Approved Countries: Argentina | Australia | Austria | Bangladesh | Brazil | Canada | Chile | Colombia | Cyprus | Dominican Republic | Ecuador | Egypt | Estonia | Germany | Greece | Hong Kong | India | Ireland | Israel | Italy | Jordan | Korea | Latvia | Lebanon | Lithuania | Malaysia | Mexico | Pakistan | Peru | Philippines | Poland | Saudi Arabia | Singapore | Slovakia | Slovenia | South Africa | Sri Lanka | Taiwan | Thailand | Tunisia | Turkey | Ukraine | United Arab Emirates | United Kingdom | United States | Uruguay | Venezuela | Vietnam
Approved Indications: Pain Unspecified | Inflammation | Pain Unspecified | Inflammation | Keratoconjunctivitis Sicca | Dry Eye Disease
Known Adverse Events: Hyperemia | Eye Pain | Pain Unspecified | Inflammation | Corneal Edema | Edema
Company: Bausch & Lomb
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: United States
Active Clinical Trial Count: 1
Highest Development Phases
Phase 3: Dry Eye Syndromes|Keratoconjunctivitis Sicca
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| CLEAN | P3 |
Completed |
Dry Eye Syndromes|Keratoconjunctivitis Sicca |
2022-11-17 |
22% |